Harnessing the CD8+ T-cell subsets with stemness for tumor immunotherapy

Wei Wang^{1

2}, Yukai He³, Sha Wu⁴

Affiliations

¹ Department of Obstetrics & Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China.
² Department of Obstetrics & Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China.
³ Georgia Cancer Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA.
⁴ Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangdong Provincial Key Laboratory of Proteomics, Guangzhou, Guangdong, PR China.

Review

Wei Wang et al. Future Oncol. 2018 Oct.

. 2018 Oct;14(24):2433-2436.

doi: 10.2217/fon-2018-0238. Epub 2018 Aug 24.

Wei Wang^{1

2}, Yukai He³, Sha Wu⁴

¹ Department of Obstetrics & Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China.
² Department of Obstetrics & Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China.
³ Georgia Cancer Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA.
⁴ Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangdong Provincial Key Laboratory of Proteomics, Guangzhou, Guangdong, PR China.

No abstract available

Keywords: CD8+ T cells; stemness; tumor immunotherapy.

Cited by

Metabolic reprogramming in the tumor microenvironment: unleashing T cell stemness for enhanced cancer immunotherapy.
Liu Y, Wang T, Ma W, Jia Z, Wang Q, Zhang M, Luo Y, Sun H. Liu Y, et al. Front Pharmacol. 2023 Dec 19;14:1327717. doi: 10.3389/fphar.2023.1327717. eCollection 2023. Front Pharmacol. 2023. PMID: 38169800 Free PMC article. Review.